According to the American Association for the Study of Liver Disease (AASLD) Guidelines, imaging is recommended as the basis for liver cancer screening in patients at risk; however, the presence of elevated alpha-fetoprotein levels appears to be an important prognostic marker. Patients with markedly elevated AFP levels typically have poorer outcomes than those with low or normal levels. The definition of high is somewhat variable, but many studies have found that patients with levels above 400 nanograms/mL tend to have a poor prognosis. At this point, however, AFP levels do not factor into treatment decisions.
CASE 2: Unresectable Hepatocellular Carcinoma
Steve C is a 56-year-old Caucasian construction worker from Miami, Florida with a history of chronic hepatitis C virus (HCV) infection and alcohol abuse.
In January of 2013 the patient was diagnosed with unresectable hepatocellular carcinoma, with an encapsulated, 7-cm tumor identified in the right lobe on Gadolinium-enhanced MRI
Multidisciplinary team recommended TACE because of patient’s ongoing alcohol use, and patient achieved a partial response (>30% decrease by RECIST criteria)
In April 2014, the patient returns for follow up
Patient’s lab values include:
AFP: 1100 ng/mL; AST 322 IU/L
ALT: 195 IU/L
Total bilirubin: 1.8 mg/dL
Platelets: 85,000
At his current workup, the patient is classified as Child Pugh Class A, with a MELD score of 13; ECOG PS is 1
MRI with gadolinium is consistent with disease progression, with encapsulated lesion in the right lobe measuring 9 cm, consistent with HCC
A third TACE procedure is recommended by the MDT
Following the TACE procedure, imaging results show 65% necrosis in the treated area with residual 1.5-cm nodules
Hope Beyond Surgery: Optimizing Care for Cholangiocarcinoma
February 15th 2024In an interview for Cholangiocarcinoma Awareness Day, Domenech Asbun, MD, discussed how the management of cholangiocarcinoma continues to evolve and addressed unmet needs in early detection and systemic therapy.
Read More
Durvalumab/Bevacizumab/TACE Significantly Extends Survival in HCC
February 6th 2024In an interview with Targeted Oncology, Bruno Sangro, MD, PhD, discussed the potential durvalumab, bevacizumab, and TACE has to set a new standard-of-care among patients with unresectable hepatocellular carcinoma.
Read More
Regorafenib Discontinuation More Likely With Poor Liver Function in Liver Cancer
January 19th 2024Patients with unresectable hepatocellular carcinoma and poor liver function were more likely to experience serious adverse effects leading to regorafenib treatment discontinuation, researchers have found.
Read More